 Phase trial recombinant human macrophage colony-stimulating factor patients invasive fungal infections phase escalation trial recombinant human macrophage colony-stimulating factor rhM-CSF combination conventional antifungal therapy marrow transplant recipients invasive fungal infection Daily doses Toxicity constitutional symptoms rhM-CSF transient dose-related thrombocytopenia Patients rhM-CSF mean reduction platelet count rhM-CSF infusion period significant patients doses rhM-CSF patients rhM-CSF allogeneic bone marrow transplantation change severity graft-versus-host disease GVHD rhM-CSF increase severity GVHD decrease effects neutrophil monocyte lymphocyte counts patients resolution infections evaluable response patients days initiation rhM-CSF Further trials rhM-CSF antifungal activity